Posted on July 19, 2021 |
By 340B Matters German drug giant Boehringer Ingelheim has unwisely joined an ignominious group of manufacturers attacking the 340B Drug Discount Program. The result will be even less resources for ...
Posted on July 1, 2021 |
By 340B Matters In the complex drug-pricing marketplace lies a murky underworld of pharmacy benefit managers (PBMs). Ostensibly, these companies negotiate lower drug pricing for insurers and (ideally) patients. They’...
Posted on June 18, 2021 |
By 340B Matters In July 2020, six huge drug companies fired the first salvo in a war against a federal program that helps safety-net healthcare providers care for the underserved. Their ...
Posted on May 26, 2021 |
By 340B Matters The Biden administration has finally acted against a reprehensible cabal of pharmaceutical companies unlawfully overcharging safety-net healthcare providers in the federal 340B Drug Discount Program. On May 17, ...
Posted on May 11, 2021 |
By 340B Matters The drug industry has an army of public relations suits busy spinning the world as Big Pharma sees it. Don’t be a patsy for one of ...